Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Moderately fractionated prostate radiotherapy with a focal boost: acute and preliminary late side effects from the phase 3 PIVOTALboost trial Presented by Isabel Syndikus 🇬🇧 #RadOnc ☢️ @estroradiotherapy.bsky.social

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨 Interim analysis of the EORTC ESTRO E2-Radiate 2011-RP ReCare cohort to assess adequacy of patient selection: Early death and adverse events after high-dose re-irradiation Presented by Nicolaus Andratschke 🇨🇭 #RadOnc ☢️ @estroradiotherapy.bsky.social

Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II) www.thelancet.com/journals/lan... FASTRACK II, the first phase 2 trial of stereotactic ablative body radiotherapy☢️ in #KidneyCancer #ESTRO26

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨 Omission of elective nodal irradiation in HNSCC: long-term results and patient-level pooled analysis from 2 prospective trials (INRT-AIR & DARTBOARD) Presenter Sympascho Young 🇺🇸

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨 Early regression index-guided dose escalation in locally advanced rectal cancer: long term results of the prospective THUNDER-2 trial Presented by Giuditta Chiloiro 🇮🇹 #RadOnc ☢️ @estroradiotherapy.bsky.social

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨 Geographic accessibility of proton therapy services in Europe: current status and opportunities for enhancement Presenter Dominik Wawrzuta 🇵🇱

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨 Prospectively validated biomarker signature for personalized radiooncology: Results of the DKTK-ROG HNprädBio biomarker trial for primary RCT of HNSCC Presenter Annett Linge 🇩🇪

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨 Best Physics Paper: Benchmarking synthetic computed tomography for radiotherapy from head to abdomen: SynthRAD2025 Grand Challenge report Presented by Matteo Maspero 🇳🇱 #RadOnc ☢️

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨 Mean dose rate-dependent skin sparing by FLASH-RT through suppressing the lysosomal membrane permeabilization-NLRP3 inflammasome axis in macrophages Presented by Chen Wang 🇨🇳 #RadOnc ☢️ @estroradiotherapy.bsky.social

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨 Agreement between patient and physician-reported symptoms during radiotherapy for prostate cancer in the HYPO-RT-PC trial Presented by Ulrika Rönningås 🇸🇪 #RadOnc ☢️ #ProstateCancer @estroradiotherapy.bsky.social

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨 Single fraction based-partial breast irradiation: 10-year results of the SiFEBI phase 2 prospective trial Presented by Laura Haas 🇫🇷 #RadOnc ☢️ #BreastCancer @estroradiotherapy.bsky.social

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨 AI-Ready Radiation Oncology: A Consensus-Built, Validated, International Knowledge Assessment for the Radiation Oncology Workforce Presented by Ciaran Malone 🇮🇪 #RadOnc ☢️

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨 Health-related quality of life in the phase III trial of Toxicity Reduction using Proton Beam Therapy for Oropharyngeal Cancer (TORPEdO;CRUK/18/010) Presented by Matthew Tyler🇬🇧 #RadOnc ☢️ @estroradiotherapy.bsky.social

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨 Five-year Results of the OPERA Trial: When and How to Assess Tumor Response to Guide Rectal Preservation Presented by Syrine Ben Dhia 🇫🇷 #RadOnc ☢️ @estroradiotherapy.bsky.social

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨 Personalising Radiotherapy Dose in Anal Cancer (PLATO) Platform: 6-month patient reported outcomes across ACT3, ACT4 and ACT5 trials Presenter Alexandra Gilbert 🇬🇧 @estroradiotherapy.bsky.social

🗣️ ESTRO26 debate: Should we delay local treatment for brain metastases in the era of targeted & immune therapies? 📅 Tue 19 May | 09:15–10:30 | A3 | ESTRO–EANO ⚖️ Immunotherapy & targeted therapy: for vs against experts https://bit.ly/4dvYodj 💬 Join the vote—where do you stand? #ESTRO26 #EANO

To celebrate🗺️World Lab Day🧪on April 23, we’re kicking off our mini-series “It All Starts with Curiosity” today. We’ll take you inside the world of LOEWE research—you’re warmly invited to join us. Feel free to share your answers in the comments section.✍🏽More ➡️ www.linkedin.com/posts/proloe...

📣 ESTRO 2026 Pre-Meeting Webinars Get ready for #ESTRO26 with two online pre-meeting webinars ahead of the congress in Stockholm (15–19 May 2026). Cases will be discussed — we can’t wait to engage with you! 🔗 Info & registration: bit.ly/4pAM9PH #PMCwebinars #ESTRO26

The #NeuroRNA team really enjoyed attending the #CancerNeuroscience meeting organised by the #EACR this week in #Bilbao. Josune Alonso and Ane Rubio presented their projects in #RNA misprocessing in #GBM @biogipuzkoa.bsky.social @helloeacr.bsky.social

Congrats to Ethan Ludmir and Chad Tang for their publication selected for recognition as part of @mdanderson.bsky.social Excellence in Science Award. #radonc #endcancer ascopubs.org/doi/10.1200/...

Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial

PURPOSEThe EXTEND trial tested the hypothesis that adding comprehensive metastasis-directed therapy (MDT) to chemotherapy would improve progression-free survival (PFS) over chemotherapy alone among pa...

ascopubs.org

Interested in #reirradiation heading to the first full day of #ESTRO25? Why not follow our 🔹Reirradiation Journey🔹 through the conference programme! Find it in the programme filter options - or below #radonc #medphys

✨We're thrilled to be taking part in #ESTRO25 in Vienna! EORTC researchers will be presenting cutting-edge findings in #RadiationOncology, a cornerstone of our scientific strategy. Find out more: www.eortc.org/blog/2025/05... @estroradiotherapy.bsky.social #CancerResearch

What a start , @mguckenberger.bsky.social with an emotional and inspiring talk at the opening Ceremony, Pascal Uffer delivered more than a talk ; if cancer were a start up. #ESTRO25 #radonc #radiotherapy

The phase III NRG/RTOG 0920 trial explored adding cetuximab to postoperative radiotherapy (RT) in 577 patients with resected intermediate-risk SCCHN. 📊 Key Findings @ascocancer.bsky.social #JCO #Onco404 #Cancer #Kanser #Oncology #HeadAndNeckCancer #RadiationTherapy #Cetuximab #ClinicalTrials #HPV

In the KEYNOTE-689 trial, neoadjuvant pembrolizumab delivered a game-changing: ✅ Event-Free Survival (EFS) Hazard Ratio: 0.73 (95% CI: 0.58–0.92) ✅ Median EFS: 51.8 months vs. 30.4 months No clear benefit seen in the hypopharynx subgroup #HNSCC #Radonc #Immunotherapy #CancerResearch

durvalumab plus tremelimumab with concurrent radiotherapy : 81% CR #radonc #GU

Treatment of Pleural Mesothelioma: ASCO Guideline Update https://buff.ly/3WrRMUm The ASCO guidelines for pleural #mesothelioma (PM) provide evidence-based recommendations for physicians on managing this condition. #LungCancer

bevacizumab, a VEGF inhibitor, in patients with platinum-resistant recurrent or metastatic nasopharyngeal carcinoma. https://buff.ly/40qpx9W

Nivolumab Improves DFS in High-Risk Head & Neck SCC The Phase 3 NIVOPOSTOP trial (680 patients) showed that adding nivolumab to standard post-op CRT significantly improved DFS in resected LA-SCCHN with high relapse risk. A trend toward better OS was observed, pending final analysis.

GORTEC Announces New Trial Success for Head and Neck Cancer Treatment

/PRNewswire/ -- GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 trial evaluating...

prnewswire.com

Our latest study, "Pulmonary Stereotactic Body Radiotherapy (SBRT) of Oligometastatic Head-and-Neck Squamous Cell Carcinoma (HNSCC): A Multicenter Retrospective Study", is now available in the @ijrobp.bsky.social www.redjournal.org/article/S036...